药物洗脱支架在冠心病超长病变择期经皮冠状动脉介入治疗中的应用

目的 评价药物洗脱支架应用于冠心病超长病变(≥50 mm)的安全性、有效性.方法 选取68例行经皮冠状动脉介入治疗(PCI)的冠心病超长病变患者置入Cypher支架、Firebird支架及Taxus支架,记录患者的治疗、在院期间和随访等情况.结果 68例患者PCI治疗均获成功,共置入Cypher支架84枚、Firebird支架42枚、Taxus支架69枚.1例合并糖尿病者术后出现支架内亚急性血栓,2例发生非Q波型心肌梗死,其他患者住院期间均无严重并发症发生.随访6～12个月,患者均未发生主要心脏不良事件,36例患者术后6～9个月行冠状动脉造影复查,其中3例发生支架内再狭窄并行外科搭桥术.结论 药物洗脱支架在冠心病超长病变PCI治疗中安全、有效,但需进一步评价.     

国产Firebird支架对急性冠脉综合征的疗效观察

目的对比研究国产雷帕霉素洗脱支架(Firebird)和进口雷帕霉素洗脱支架(Cypher)对急性冠脉综合征(ACS)患者12个月疗效。方法选取ACS患者220例均于发病后12h内行急诊介入治疗(PCI),随机分为Firebird支架和Cypher支架两组,其中Firebird支架组120例,Cypher支架组100倒。220例患者共植入Firebird支架142枚,Cypher支架112枚。结果两组患者靶血管特征差异无显著性(P均>0.05)。两组患者靶血管直径和靶病变长度对比(P均>0.05)。临床随访1年,两组均各有1例急性支架内血栓形成,各有1例死亡。无亚急性、慢性血栓形成、再发心肌梗死。再发心绞痛、再次血运重建和主要心血管事件(MACE)比较差异无显著性(P均>0.05)。结论国产和进口雷帕霉素洗脱支架治疗ACS近期疗效相似。     

国产爱克赛尔药物洗脱支架与Cypher药物洗脱支架、金属裸支架在冠心病介入治疗近、中期疗效的比较

目的：探讨国产爱克赛尔药物洗脱支架、进口Cypher药物洗脱支架、金属裸支架治疗急性心肌梗死（AMI）或不稳定型心绞痛（UA）临床疗效的差异。方法：将126例在我院行PCI的冠心病患者分为三组,爱克赛尔药物洗脱支架组（65例）,进口Cypher药物洗脱支架组（36例）,金属裸支架组（25例）,分析支架置入后6个月的支架内血栓发生率及6个月再狭窄率。结果：三组患者在术后血管通畅,心功能和住院期间心脏事件方面差异均无统计学意义,6～8个月后随访时,均无支架内血栓发生,国产爱克赛尔药物洗脱支架组的支架内再狭窄率为5.9%;进口Cypher药物洗脱支架组的支架内再狭窄率为3.7%;裸支架组的支架内再狭窄率为33.3%。结论：国产爱克赛尔药物洗脱支架、进口Cypher药物洗脱支架治疗AMI患者并未增加6个月内支架内血栓的发生,再狭窄率两者差异无统计学意义;与裸支架相比,两者6个月的再狭窄率显著降低。     

国产药物洗脱支架在急性冠脉综合征中的应用

目的：探讨国产药物洗脱支架（Firebird支架）在急性冠脉综合征急诊介入治疗中应用的安全性和有效性.方法：2004年10月～2005年7月间治疗急性冠脉综合征患者86例,所有患者均于发病12h内行急诊经皮冠状动脉介入治疗（PCI）.治疗时随机置入Firebird支架或Cypher支架.Firebird支架组46例,Cypher支架组40例.结果：86例患者急诊PCI治疗均获得成功.Firebird组46支罪犯血管置入53枚Firebird支架,Cypher组40支罪犯血管置入49枚Cypher支架.其中1例置入Cypher支架者术后出现脑出血而死亡.Firebird支架组和Cypher支架组比较,PCI术后TIMI3级率和并发症发生率无显著性差异.对85例患者进行了3～6个月的随访,两组患者均未发生任何心血管事件,术后6个月Firebird支架组有20例（43%）行冠状动脉造影检查,无一例发生支架内再狭窄;Gypher支架组有19例（49%）行冠状动脉造影检查,1例发生支架内再狭窄,两组再狭窄率无显著性差异.结论：Firebird支架在急性冠脉综合征急诊介入治疗中应用有较好的安全性和有效性.     

Cypher雷帕霉素药物洗脱支架在急性ST段抬高心肌梗死中的临床观察

目的:观察Cypher雷帕霉素药物洗脱支架在急性ST段抬高心肌梗死(ASTEMI)中的临床研究.方法:入选2003年10月至2005年6月确诊ASTEMI患者76例行急诊冠脉造影和PCI,冠脉造影后明确病变,然后行PTCA及支架置入.在PCI过程中置入Cypher西罗莫司药物洗脱支架.观察术中、住院、出院后有无严重心脏不良事件(包括死亡、非致命急性心肌梗死、靶病变靶血管重建率、再次入院).结果:所有患者均经桡动脉行介入治疗,冠脉造影和支架的成功率为100%.共置入Cypher支架86枚,置入1个支架的患者为66例,置入2个支架的为10例.在支架长度中,支架≥28mm的有38枚支架,＜28mm的有48枚支架.在支架直径中,支架≥3.0mm的有76枚支架,＜3.0mm的有10个支架.放入支架后梗死相关血管前向血流达TIMI3级的有69例,发生无复流的有3例,它们在术中、术后均应用Tirofiban.3例患者(3.9%)在住院期间发生不良事件.1个月随访发现1例三支血管病变患者在出院后1周猝死.出院后4～6个月以上随访有4例患者出现心绞痛入院行冠脉造影.其余患者无不适症状等.共有11例患者(14.4%)在支架术后4～7个月复查冠脉造影,再狭窄率为0%.4例出现心绞痛患者造影发现其它血管狭窄(既往存在)而行支架.结论:Cypher雷帕霉素药物洗脱支架在ASTEMI中的应用是安全和有效的,明显减少再狭窄率.     

Zotarolimus洗脱支架与雷帕霉素洗脱支架临床应用比较

目的 对比研究Zotarolimus洗脱支架和进口雷帕霉素洗脱支架(Cypher支架)临床应用疗效.方法 129例符合冠脉介入手术指征的冠脉病变患者被随机分为两组,Zotarolimus洗脱支架植入组和Cypher支架植入组,其中Cypher支架组65例,Zotarolimus洗脱支架组64例.植入Cypher支架83枚,植入Zotarolimus支架80枚.结果 两组患者平均靶病变长度和置入支架长度Cypher支架组对比Zotarolimus洗脱支架组分别为:(18.72±5.96)mm比(19.42±6.21)mm,(24.67±7.81)mm比(25.56±6.98)mm,差异无显著性(P>0.05).临床随访观察,再发心肌梗死及死亡,再发心绞痛、再次血运重建和主要心血管事件对比,均差异无显著性.但Cypher支架组支架内亚急性及迟发性血栓形成率显著高于Zotarolimus洗脱支架组,为3.1%比0.结论 与Cypher支架相比,Zotarolimus洗脱支架在预防再狭窄、减少近期心血管事件方面疗效相似,但具有更低支架内亚急性血栓及迟发性发生率.     

雷帕霉素洗脱支架在冠心病的临床疗效

目的　观察雷帕霉素洗脱支架 (Cypher)治疗冠状动脉病变的临床效果。　 方法　 17例冠心病患者植入Cypher支架 ,治疗 2 3处病变 ,包括左前降支 (LAD) 15处、左回旋支 (LCX) 3处、右冠状动脉 (RCA) 5处 ;5例支架内再狭窄病变分别为LAD 4例和RCA 1例。术前病变狭窄程度 75 %～ 95 %。　结果　 17例患者共治疗 2 3处病变 ,植入Cypher支架 2 3个 ,手术即刻成功率 10 0 % ;术后残余狭窄 <5 % ,血流TIMI 3级。所有患者术中无并发症 ,术后临床随访 3～ 16个月 ,无心脏事件发生。 4例患者术后 6个月复查冠状动脉造影示病变血管支架植入处管腔通畅 ,无内膜增生征象。　结论　Cypher支架植入成功率高 ,可通过抑制血管内膜增生及支架本身拮抗病理性血管重塑的作用 ,有效降低再狭窄的发生 ,近中期疗效满意 ,安全性较高。     

国产生物降解涂层雷帕霉素洗脱支架在急性ST段抬高心肌梗死急诊经皮冠状动脉介入中的应用

目的探讨急性sT段抬高心肌梗死（STEMI）急诊经皮冠状动脉介入治疗（PCI）中应用国产生物降解涂层雷帕霉素洗脱支架（EXCEL）的安全性和有效性。方法69例sTEMI患者69处病变行PcI治疗,共置入82枚EXCEL。观察住院期间和6—12个月随访期间的心血管事件及支架内再狭窄的发生。结果68例PCI取得成功,1例术后第4天死于亚急性血栓形成。临床随访12个月,2例出现心绞痛,1例术后7个月再次行PCI。68例患者中复查冠状动脉造影18例,无支架内再狭窄17例,支架内再狭窄1例,无其他主要不良心血管事件发生。结论EXCEL在STEMI患者急诊PCI中应用有较高的安全性和有效性。     

Zotarolimus洗脱支架和雷帕霉素洗脱支架的临床疗效对比观察

目的 对比研究Zotarolimus洗脱支架和进口雷帕霉素洗脱支架（Cypher支架）临床应用疗效。方法 129例符合冠脉介入手术指征的冠脉病变患者被随机分为两组,Zotarolimus洗脱支架植入术组和Cypher支架植入术组,其中Cypher支架组65例,Zotarolimus洗脱支架64例。植入Cypher支架83枚,植入Zotarolimus支架80枚。结果 两组患者平均靶病变长度和置入支架长度Cypher支架组对比Zotarolimus洗脱支架组分别为：(18.72+5.96)mm比(19.42+6.21)mm,(24.67+7.81)mm比(25.56+6.98)mm,显著无差异性（P >0.05）。临床随访观察,再发心肌梗死及死亡,再发心绞痛、再次血运重建和主要心血管事件对比,均P>0.05,统计学无差异性。但Cypher支架组支架内亚急性及迟发性血栓形成率高于Zotarolimus洗脱支架组,为3.1%比0,P ＜0.05,结论 与Cypher支架相比,Zotarolimus洗脱支架在预防再狭窄,减少近期心血管事件方面疗效相似,但具有更低支架内亚急性血栓及迟发性发生率。     

雷帕霉素洗脱支架在合并糖尿病的冠心病患者介入治疗中的临床应用

目的观察雷帕霉素洗脱支架在合并糖尿病的冠心病患者介入治疗中的疗效及安全性。方法合并糖尿病的冠心病患者98例作为研究对象,所有患者常规Judkins法冠状动脉造影(CAG),狭窄程度在75%以上的患者进行介入治疗。42例置入Cypher雷帕霉素药物洗脱支架(DES组),56例置入普通支架(BMS组)。所有患者术前术后常规给予阿司匹林和氯呲格雷等药物治疗,术后严格控制冠心病危险因素。结果98例合并糖乐病的患者CAG显示2支以上血管病变者占70．4%,且以B型病变和C型病变为多。DES组共置入Cypher药物支架77个,BMS组共置入普通支架99个,PCI均获成功。所有患者进行了10．2±3．7个月的随访,DES组复发心绞痛的患者5例(11．9%),无心肌梗死和死亡发生；BMS组复发心绞痛14例(25．0%),非致死性再梗死3例,心源性死亡4例,非心源性死亡2例；DES组在心源性死亡、非致死性再梗死和复发心绞痛方面低于BMS组,有统计学差异。DES组11例复查CAG,有2例Cypher药物支架靶病变处出现再狭窄,BMS组18例患者复查CAG,11例出现支架再狭窄。对狭窄超过75%的靶病变进行了再次血管成形术。结论雷帕霉素洗脱支架在合并糖尿病的冠心病患者中应用是安全有效的,不增加急性或亚急性血栓形成的机会,有助于减少支架置入术后再狭窄的发生,不良心血管事件发生率低,近期和远期疗效良好。     

Incidence of thrombosis after implantation of drug-eluting stents in patients with coronary artery disease

Background Randomized clinical trials have demonstrated equivalent safety to bare-metal stents after drug-eluting stents （DES） implantation. However, the DES thrombosis in randomized trials could not be comparable to those observed in clinical practice, frequently including off-label indications. This study sought to assess the incidence of DES thrombosis after implantation of DES in patients with real world coronary artery disease （CAD） in China.
Methods From December 2001 to April 2007, 8190 consecutive patients received the treatment with DES, 5412 patients completed one year follow-up： 2210 with sirolimus-eluting stent Cypher, 1238 with paclitaxel-eluting stent Taxus and 1964 with Chinese sirolimus-eluting stent Firebird, After two years of follow-up, there were 2176 patients （1245 Cypher, 558 Taxus and 373 Firebird）. All patients were treated with aspirin and clopidogrel over at least 9 months.
Results Among 8190 patients, 17 patients had acute stent thrombosis （0.24%）： 7 in the Cypher group, 4 Taxus and 6 Firebird; 23 patients had subacute stent thrombosis： 8 Cypher, 6 Taxus and 9 Firebird. The incidence of acute and subacute thrombosis was 0.49%： 0.50% Cypher, 0.63% Taxus and 0.41% Firebird. The incidence of late thrombosis at one year followup was 0.63%： 0.63% Cypher, 0.88% Taxus and 0.46% Firebird; at two year follow-up the incidence was 0.74%： 0.72% Cypher, 0.90% Taxus and 0.54% Firebird. There was no significant difference among three groups at 1 year and 2 years follow-up.
Conclusion The first generation DES in the treatment of complex lesions are safe and effective if patients are aggressively treated with dual antiplatelet agents.     

冠状动脉药物支架再狭窄形式分析

目的:分析冠状动脉支架置入后造影复查的影像资料,寻找不同药物支架再狭窄的特点。方法:收集冠状动脉介入治疗后造影复查再狭窄患者121例,共159处病变,进行再狭窄形式分析。结果:裸支架(BMS)和药物支架(DES)后再狭窄病变局限性再狭窄分别占39.80%和70.49%(P<0.001);弥漫性再狭窄病变分别占60.20%和29.51%(P<0.001);三种不同类型DES(Cypher,Taxus和Firebird)再狭窄形式没有差异,局限性再狭窄分别为83.33%,55.56%和75.00%(P=0.070);弥漫性再狭窄分别占16.67%,44.44%和25.00%,(P=0.070)。结论:①DES改变了以往BMS再狭窄模式,由弥漫型转为局限型;②不同种类的药物支架再狭窄形式没有差异。     

Comparison of in-hospital and long-term outcomes between a Cypher stent and a Taxus stent in Chinese diabetic patients with coronary artery disease

Background  The sirolimus and paclitaxel distribution patterns and tissue residence time may be modified in atherosclerotic lesions for patients with diabetes, and the biological mechanisms of action for these agents differ significantly. Previous clinical trials have yielded discrepant results of major adverse cardiac events and restenosis between a sirolimus-eluting stent and a paclitaxel-eluting stent in coronary artery disease. Therefore, this study was conduced to compare in-hospital and long-term clinical outcomes between patients receiving sirolimus-eluting stent (Cypher or Cypher Select stent) and paclitaxel-eluting stent (Taxus Express stent) after percutaneous intervention (PCI) in Chinese patients with diabetes.
Methods  One hundred and sixty-four consecutive diabetic patients underwent PCI in Fuwai Hospital from April 2004 to December 2004. Of them, 101 patients received Cypher or Cypher Select stents (Cypher group, 145 stents) and 63 patients received Taxus Express stents (Taxus group, 129 stents). Repeat coronary angiography was performed at 6-month and clinical outcomes were evaluated at 1- and 3-year follow-up. Stent thrombosis was classified according to Academic Research Consortium (ARC).
Results  The two groups did not differ significantly with respect to cardiac death, recurrent myocardial infarction (re-MI), target vessel revascularization (TVR) and occurrence of major adverse cardiac events (MACE). And the MACE-free cumulative survival at 1- and 3-year follow-up and early, late and very late thrombosis rates were also similar in the two groups (all P>0.05). There was a trend favoring PES over SES with regard to reducing cardiac death (0 vs 2.0%, P=0.524), re-MI (0 vs 2.0%, P=0.524), the composite of the cardiac death and re-MI (0 vs 4.0%, P=0.299) and very late thrombosis (0 vs 3.0%, P=0.295) between 1-year and 3-year follow-up.
Conclusion  The study indicates that PCI with either Cypher or Taxus stents is associated with similar efficacy and safety in the small population of Chinese diabetic patients during long-term follow-up.

     

冠状动脉支架内急性亚急性血栓形成的诊治体会

目的探讨冠状动脉支架内急性亚急性血栓形成的原因和处理方法。方法回顾性分析我院开展冠脉介入手术以来发生的诊断明确的冠脉支架内急性亚急性血栓形成的5例患者的病历资料。结果 9年间总共有928例患者行冠脉介入手术,共发生冠脉支架内急性亚急性血栓形成5例,发生率0.54%。冠脉支架内急性亚急性血栓形成与冠脉血管病变长,严重钙化病变,血管细小,支架膨胀不全,支架贴壁不良,支架未完全覆盖病变,支架重叠连接处未重整,术后未坚持应用双联抗血小板药物及抗血小板药物抵抗有关。冠脉支架内急性亚急性血栓形成对溶栓效果不佳,需急诊行PTCA、血栓抽吸导管开通相关血管,并强化抗凝抗血小板治疗。结论冠脉支架内急性、亚急性血栓形成与患者血管病变特点及介入操作等因素有关。再次急诊PTCA、血栓抽吸导管开通相关血管是治疗支架内血栓形成的首选方法。     

Comparison of the incidence of late stent thrombosis after implantation of different drug-eluting stents in the real world coronary heart disease patients: three-year follow-up results

Background Late stent thrombosis （LST） is still concerned by interventions cardiologists in daily clinical practice. This study aimed to compare the incidence of LST after implantation of different drug-eluting stents （DES） in coronary heart disease （CHD） patients in the real world.Methods From December 2001 to February 2009, a total of 11 875 consecutive CHD patients undergone DES implantation were enrolled in this single-center registery study. Patients with acute ST-segment elevation myocardial infarction, mixed DES implantation, restenosis lesions, and patients who could not take dual antiplatlet medication and those who were contraindicated for coronary interventional treatment were excluded. All patients were treated with completed dual antiplatelet medications for at least 9 months after DES deployment. The follow-up was completed by outpatient visits, letter correspondence, phone calls and coronary angiography. Definite LST was diagnosed auording to the Academic Research Consortium （ARC） definition.Results Cypher or Cypher Select stents were implanted in 4104 cases, Taxus or Taxus Liberty stents in 2271 cases and Firebird stents （Chinese rapamycin-eluting stents） in 5500 cases. One-year follow-up was completed in 9693 patients, including 3346 cases with Cypher or Cypher Select stents, 1529 cases with Taxus or Taxus Liberty stents and 4818 cases with Firebird stents. Two- and three-year follow-up results were obtained in 7133 and 4353 patients, respectively, including 2410 and 1760 cases with Cypher or Cypher Select stents, 1285 and 900 cases with Taxus or Taxus Liberty stents as well as 3438 and 1693 cases with Firebird stents. One-year follow-up results showed that the incidence of LST was 1.08% in patients with Cypher or Cypher Select stents, 1.24% in those with Taxus or Taxus Liberty stents and 0.71% in those with Firebird stents; there was no significant difference between those with Cypher or Cypher Select and Firebird stents, but there was significant difference between those with Taxus or Taxus Liberty and Firebird stents （P=0.044）. The incidence of LST at the 2- and 3-year follow-up was 1.33% and 1.70% in those with Cypher or Cypher Select stents, 1.40% and 1.70% in those with Taxus or Taxus Liberty stents, and 0.83% and 0.95% in those with Firebird stents, respectively. There were no significant differences among the three groups.Conclusions This study indicates that first-generation DES are acceptable to treat complex coronary lesions, and there is no significant difference of LST for three different DES.     

28例肝素膜支架的临床分析

为评价肝素膜支架对防止急性／ 亚急性支架内血栓形成的有效性及其对远期再狭窄的影响,对２８ 例病人的３２ 个靶病变置入肝素膜支架。结果手术成功率１００ ％ ,术后无１ 例急性／ 亚急性血栓形成,术后随访６ ～２４ 月,５ 例复发心绞痛（１７ ．９ ％ ） ,３ 例经冠状动脉造影证实再狭窄,无死亡病例。结果提示：肝素膜支架对于防止急性／ 亚急性支架内血栓形成是有效的,但不能降低远期再狭窄率。     

血管内支架在冠状动脉复杂病变成形术中的临床应用

本文报道了 31例冠心病患者冠状动脉复杂病变在经皮冠状动脉成形术 (PTCA)并发急性血管内闭塞、内膜严重撕裂、术后显著残留狭窄及短期内再狭窄等的情况下行冠状动脉内支架植入术 (CASI) ,均获成功 ,术后急性血管闭塞和内膜撕裂征象消失 ,残留狭窄及再狭窄解除 ,未出现出血和穿刺部位血管并发症及CASI后亚急性血栓形成。随访 2 6例 ,1例术后 1 3天发生猝死 ,2例因胸痛复发经造影证实支架血管再狭窄 ,再次球囊扩张后再狭窄有所改善 ,余 2 3例冠状动脉造影示支架血管正常 ,结果表明 ,冠心病复杂冠状动脉病变行CASI是解除PTCA急性并发症的安全有效的方法 ,亦有助于PTCA后再狭窄的防治。     

A comparison of clinical and angiographic outcomes after Excel bioabsorbable polymer versus Firebird durable polymer rapamycin-eluting stent for the treatment of coronary artery disease in a “real world” setting: six-month follow-up results

Background Several clinical trials have shown that rapamycin-eluting stents significantly reduce the risk of restenosis after percutaneous coronary intervention (PCI). The Firebird stent and the Excel stent (coated with bioabsorbable polymer) are two different types of rapamycin-eluting stents made in China, both have been recently approved for clinical use in China by State Food and Drug Administration. However, it is unclear whether there are differences in safety and efficacy between the two types of stents in daily practice. Methods In the month of June 2006, a total of 190 consecutive patients were treated exclusively with Firebird stents (n=93, Firebird group) or Excel stents (n=97, Excel group) in our center and were included in this study. The frequency of major adverse cardiac events (MACE, a composite of death, myocardial infarction or target lesion revascularization), binary restenosis, and late lumen loss and stent thrombosis during a six-month follow-up period were compared between the two groups.Results Patient and lesion characteristics were comparable between the groups. Major adverse cardiac event rates were low in hospital and at 6 months (2.1% in the Excel group and 0% in the Firebird group, P﹥0.05). The 6-month angiographic in-stent restenosis rate was 0% in both groups, with an associated late loss of (0.15 ± 0.21) mm versus (0.14 ± 0.20) mm (P=0.858) and the in-segment restenosis rate was also 0% for the Excel group and the Firebird group. There was no definite stent thrombosis identified in either group during the six-month follow-up period and only one patient in the Excel group had probable stent thrombosis in hospital. Conclusions Results from this mid-term, single-center study showed that both of the Firebird and the Excel rapamycin eluting stent had similar effects on reducing the incidence of MACE and the risk of restenosis (both in-stent and in-segment binary restenosis) after PCI in daily practice.     

Firebird and Cypher sirolimus-eluting stents and bare metal stents in treatment of very long coronary lesions

Background As a kind of sirolimus-eluting stent （SES） made in China, Firebird SES is more effective than bare metal stent （BMS） and not inferior to Cypher SES for short coronary lesions in terms of reduction of restenosis and revascularization. However, Firebird SES does not show any benefits in patients with a very long coronary lesion （VLCL）. The present study was undertaken to evaluate the safety and efficacy of Firebird SES for VLCL by comparison of Cypher SES and BMS. Methods In this prospective, nonrandomized and comparative study, eligible patients with de novo coronary lesion （≥ 30 mm） between January 2005 and June 2006 were allocated into Firebird SES group, Cypher SES group or BMS group. They were subjected to an angiographic follow-up of 6 months and a clinical follow-up of 12 months. The primary endpoints constitute the in-stent and in-segment restenosis rates at 6 months. The secondary endpoint was defined as a major adverse cardiovascular event （MACE） that was a 12-month combined endpoint of all-cause deaths, reinfarction or in-stent thrombosis, and target-lesion revascularization. The 12-month in-stent thrombosis was also evaluated to address the safety of Firebird SES implantation exceptionally. Results A total of 468 patients were assessed for eligibility. Of 113 patients who were finally included according to the prior inclusion and exclusion criteria, 39 （41 lesions） were treated with Firebird SES, 37 （39 lesions） with Cypher SES, and 37 （37 lesions） with BMS. There were no significant differences in the baseline characteristics between the three groups; but there were longer lesions, more frequent use of overlapping stent in the Firebird SES group and the Cypher SES group. Angiographic follow-up showed that the rates of binary stenosis were similar between the Firebird SES group and the Cypher SES group （in-segment： 14.6% vs 12.8%, relative risk （RR）1.14, P=0.81; in-stent： 9.8% vs 10.3%, RR 0.95, P=0.94）, and significantly lower than those in the B